Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Zebra 365 who wrote (9217)	6/5/1998 8:44:00 AM
From: regine	Read Replies (1) \| Respond to of 23519

TO ALL! BETTER HOLD ON TO YOUR SHARES OR BUY NOW!!! Friday June 5, 7:31 am Eastern Time Company Press Release VIVUS Responds to Reports of "Disappointing Results" With MUSE MOUNTAIN VIEW, Calif.--(BW HealthWire)--June 5, 1998--VIVUS, Inc. (NASDAQ:VVUS - news) today responded to media reports about ''disappointing results'' data presented at the American Urological Association (AUA) annual meeting earlier this week in San Diego, CA. VIVUS would like to refer patients and physicians to the efficacy data of MUSE(R)(alprostadil) amassed from 71 worldwide clinical trial sites and involving nearly 1,800 patients. Additional new data on the efficacy of MUSE in clinical practice are scheduled for presentation at the American Diabetes Association meeting to be held June 13-16 in Chicago, IL. The abstract presented at the AUA by researchers from Presbyterian Hospital in Dallas, TX stated that ''only 27% of patients achieved rigidity sufficient for intercourse despite being challenged to the highest dose.'' In discussing his study results, the presenting physician clarified that not all men were challenged to the highest doses (500 or 1000 mcg) of MUSE, and that only 10 of these 115 patients (or 9%) were administered the 1000 mcg dose. In VIVUS' clinical trials of MUSE, between 41% and 65% of men required the 1000 mcg dose to achieve rigidity sufficient for intercourse. The efficacy of MUSE was established in part through the VIVUS Phase III clinical study which was the basis of Food and Drug Administration (FDA) approval of MUSE in November 1996. This 58-site U.S. study reported in the New England Journal of Medicine in January 1997 found that 66% (996/1511) of men with severe, organic erectile dysfunction were able to achieve an erection sufficient for intercourse in a clinic setting. A more recent 13-site study of MUSE conducted in five European countries and reported in this month's issue of the British Journal of Urology found that 64% (159/249) of men with severe, organic erectile dysfunction achieved an erection sufficient for intercourse in a clinic setting. Patients in these two VIVUS-sponsored clinical studies received doses of MUSE up to and including the highest (1000 mcg) dose. Currently, over 80% of all prescriptions for MUSE are at the 500 or 1000 mcg dose level. ''Efficacy of MUSE is clearly dose dependent,'' said Tom Lue, MD, Professor of Urology, University of California, San Francisco. ''In my clinical practice, most patients require dosing of MUSE at the 500 or 1000 mcg level.'' Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE(R)(alprostadil). MUSE is a therapy which consists of a proprietary, non-invasive drug delivery system applied into the urinary opening, and is not for men with sickle cell trait, disease or other blood disorders. One third of men reported genital pain, causing some to stop use. A few men reported dizziness and, rarely, fainting. Note to Editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). Contact: VIVUS Nina W. Ferrari or David Yntema, 650/934-5200

To: Zebra 365 who wrote (9217)	6/5/1998 9:21:00 AM
From: Frostman	Read Replies (1) \| Respond to of 23519

Zebra, WSJ interactive picked up the story this morning as well.. ************************ Vivus: Efficacy Of Muse Impotence Pdt Is 'Dose Dependent' Dow Jones Newswires MOUNTAIN VIEW, Calif. -- Vivus Inc. (VVUS) said the efficacy of its impotence drug, Muse, is "dose dependent." The company was responding to recent media reports about "disappointing results" presented by Dallas researchers at the American Urological Association annual meeting earlier this week. In a press release Friday, Vivus said the data, which indicated that 27% of patients achieved rigidity sufficient for intercourse, were based on a study in which not all men were challenged to the highest doses (500 or 1,000 mcg) of Muse. The company said only 9% of the patients in the study received the 1,000-mcg dose. Vivus said in its own trials, between 41% and 65% of men required the 1,000-mcg dose to achieve rigidity sufficient for intercourse....>> etc etc. *****************************